Mercury Laboratories Limited (BOM:538964)
750.00
-48.00 (-6.02%)
At close: Nov 6, 2026
Mercury Laboratories Revenue
Mercury Laboratories had revenue of 193.87M INR in the quarter ending September 30, 2026, with 1.99% growth. This brings the company's total for the last twelve months to 732.23M, down -5.37% year-over-year. In the fiscal year ending March 31, 2026, Mercury Laboratories had annual revenue of 759.37M with 1.11% growth. That makes Mercury Laboratories the 38,408th largest company in the world by revenue and 3,481st in India.
Revenue (ttm)
732.23M
Revenue Growth
-5.37%
P/S Ratio
1.23
Revenue / Employee
1.44M
Employees
510
Market Cap
900.00M
Revenue by Geography
- India 512.14M 67.4%
- Export 247.23M 32.6%
Fiscal year ended Mar 31, 2026 See the full Mercury Laboratories breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 759.37M | 8.36M | 1.11% |
| Mar 31, 2025 | 751.01M | -4.58M | -0.61% |
| Mar 31, 2024 | 755.59M | 2.25M | 0.30% |
| Mar 31, 2023 | 753.34M | 174.10M | 30.06% |
| Mar 31, 2022 | 579.24M | -106.78M | -15.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Parnax Lab | 2.52B |
| Godavari Drugs | 1.11B |
| Concord Drugs | 860.69M |
| Source Natural Foods and Herbal Supplements | 796.24M |
| Speciality Medicines | 752.85M |
| Shelter Pharma | 731.34M |
| Amwill Health Care | 469.16M |
| Cian Healthcare | 282.99M |